The Return Trends At Kinatico (ASX:KYP) Look Promising
We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
Understanding Return On Capital Employed (ROCE)
For those that aren't sure what ROCE is, it measures the amount of pre-tax profits a company can generate from the capital employed in its business. The formula for this calculation on Kinatico is:
Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)
0.034 = AU$919k ÷ (AU$33m - AU$6.6m) (Based on the trailing twelve months to December 2024).
Thus, Kinatico has an ROCE of 3.4%. In absolute terms, that's a low return and it also under-performs the IT industry average of 5.7%.
Check out our latest analysis for Kinatico
In the above chart we have measured Kinatico's prior ROCE against its prior performance, but the future is arguably more important. If you're interested, you can view the analysts predictions in our free analyst report for Kinatico .
What Can We Tell From Kinatico's ROCE Trend?
The fact that Kinatico is now generating some pre-tax profits from its prior investments is very encouraging. Shareholders would no doubt be pleased with this because the business was loss-making five years ago but is is now generating 3.4% on its capital. In addition to that, Kinatico is employing 282% more capital than previously which is expected of a company that's trying to break into profitability. This can tell us that the company has plenty of reinvestment opportunities that are able to generate higher returns.
In another part of our analysis, we noticed that the company's ratio of current liabilities to total assets decreased to 20%, which broadly means the business is relying less on its suppliers or short-term creditors to fund its operations. Therefore we can rest assured that the growth in ROCE is a result of the business' fundamental improvements, rather than a cooking class featuring this company's books.
The Bottom Line
To the delight of most shareholders, Kinatico has now broken into profitability. And with the stock having performed exceptionally well over the last five years, these patterns are being accounted for by investors. With that being said, we still think the promising fundamentals mean the company deserves some further due diligence.
One more thing, we've spotted 2 warning signs facing Kinatico that you might find interesting.
While Kinatico isn't earning the highest return, check out this free list of companies that are earning high returns on equity with solid balance sheets.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
If You'd Invested $1,000 in AbbVie (ABBV) Stock 10 Years Ago, Here's How Much You'd Have Today
Key Points If you'd invested in AbbVie 10 years ago, you would likely be pleased. The drugmaker has paid and grown its dividend quite well over this period. Its two immunosuppressants, Skyrizi and Rinvoq, have seen expanding sales. 10 stocks we like better than AbbVie › Think back to 10 years ago. The New England Patriots and their quarterback Tom Brady were accused of underinflating footballs. The Supreme Court affirmed same-sex marriage nationwide. And Apple introduced its Apple Watch. Also, as happens in every year, many investors bought stocks. What if you'd spent $1,000 on shares of AbbVie (NYSE: ABBV) stock a decade ago? What would that stake be worth now? It would be worth $3,350 -- or, if you'd reinvested your dividends in additional shares of AbbVie stock, it would be worth $4,105. That's because AbbVie is a solid dividend payer, with a recent dividend yield of 3.4%. It's a dividend grower, too. Its total annual payout was recently $6.47 per share, up from $5.64 in 2022 and $3.59 in 2018. Before you kick yourself about missing out on this investment, know that it was actually close to average, with dividends not reinvested. AbbVie's average annual gain was 12.84%, compared to 12.62% for the S&P 500 index. When you reinvest dividends for both, AbbVie is more clearly ahead, 15.17% vs. 13.59%. AbbVie was spun off from Abbott Laboratories in 2013, and it's a major global pharmaceutical company with a recent market value topping $330 billion. The company is known for treatments in the fields of immunology, oncology, aesthetics, neuroscience, and eye care. A downside for investors is that it lost patent protection for its blockbuster drug Humira -- but it has a promising pipeline of drugs in development, and two immunosuppressants, Skyrizi and Rinvoq, have been selling well. It's not too late to invest in AbbVie if you like what you see with the company. At recent levels, the stock seems neither wildly overvalued nor undervalued. Its recent price-to-sales ratio of 5.9 is a bit above its five-year average of 4.7, but that's not necessarily a deal-breaker for long-term investors. Perhaps in 2035, you'll be looking back and smiling. Do the experts think AbbVie is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did AbbVie make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,019% vs. just 178% for the S&P — that is beating the market by 841.12%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Selena Maranjian has positions in AbbVie and Apple. The Motley Fool has positions in and recommends AbbVie, Abbott Laboratories, and Apple. The Motley Fool has a disclosure policy. If You'd Invested $1,000 in AbbVie (ABBV) Stock 10 Years Ago, Here's How Much You'd Have Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
ON Semiconductor Corporation (ON): A Bull Case Theory
We came across a bullish thesis on ON Semiconductor Corporation on CopyCat Invest's Substack. In this article, we will summarize the bulls' thesis on ON. ON Semiconductor Corporation's share was trading at $58.05 as of July 30th. ON's trailing and forward P/E were 40.31 and 25.84, respectively according to Yahoo Finance. Despite a sharp pullback in the stock following cautious reports from peers like Texas Instruments (TXN), NXP (NXPI), and STMicroelectronics (STM), the author sees a differentiated setup for ON. The broader semiconductor space faces uncertainty around the pace of recovery and supply chain normalization, but ON's multi-year manufacturing optimization and recent cost restructuring, announced in Q4 2024, provide a foundation for improving fundamentals. The company is expected to begin realizing solid free cash flow as it works through elevated inventories that were strategically accumulated to support its fab transitions. While the market appears ready to punish ON's upcoming earnings report, this negative sentiment may have already been priced in, creating a favorable entry point. The author acknowledges the risk of further downside but is prepared to add more if the stock weakens post-earnings. From a valuation perspective, ON is no longer as inexpensive on a trailing earnings basis as it was near previous highs—a typical trait of cyclical semiconductor stocks—but remains considerably cheaper than TXN, which trades near all-time highs despite meaningful earnings declines. Moreover, ON's operational resilience and differentiated trajectory stand out versus peers like STM, whose recent performance has been weaker. The author sees the current setup as a compelling opportunity to build exposure to a company with improving cash generation, margin tailwinds, and an attractive relative valuation within the semiconductor landscape. Previously, we covered a bullish thesis on ON Semiconductor Corporation (ON) by Charly AI in January 2025, which highlighted the company's exposure to EVs, industrial automation, and clean energy. The company's stock price has appreciated by approximately 4.38% since our coverage. This is because the thesis hasn't fully played out yet. The thesis still stands as long-term fundamentals remain intact. Copycat shares a similar view but emphasizes near-term resilience and valuation. ON Semiconductor Corporation is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 44 hedge fund portfolios held ON at the end of the first quarter which was 52 in the previous quarter. While we acknowledge the potential of ON as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None.
Yahoo
an hour ago
- Yahoo
Palantir stock surges after company reports first billion-dollar quarter
Palantir (PLTR) stock surged in after-hours trading on Monday after the company reported second quarter results that beat analyst estimates across the board as its revenue topped $1 billion in a quarter for the first time. "The growth rate of our business has accelerated radically," Palantir CEO Alex Karp said. "Yet we see no reason to pause, to relent, here." Shares in the defense technology giant were up more than 4% in after-hours trade on Monday. In its second quarter, Palantir posted earnings per share of $0.16, beating consensus estimates of $0.14 and up 77% from the same quarter last year. Revenue came in at $1.004 billion, Palantir's first quarter surpassing the billion-dollar mark on a quarterly basis. The company's top line also beat analyst forecasts for $939.25 billion and was up 48% year-over-year. US commercial revenue came in at $306 million, growing 93% year-over-year, while US government revenue for the quarter was $426 million, up 53% from the same quarter last year. Analysts had estimated that sales for the two sectors would come in at $273 million and $391 million, respectively. In May, shares of Palantir fell 12% the day after its first quarter results as investors scrutinized the company's valuation and declining sales in its international commercial business, which sells software to businesses abroad, even as its first quarter revenue blew past Wall Street's forecasts. On Monday, Palantir raised its 2025 full-year revenue guidance to $4.14-$4.15 billion, above Wall Street's estimate of $3.91 billion. The company also noted in its report that it closed $2.27 billion of total contract value in the quarter, up 140% from the same quarter last year. Karp attributed much of the company's success to Palantir's integration of AI technology into its offerings. "It has been a steep and upward climb—an ascent that is a reflection of the remarkable confluence of the arrival of language models, the chips necessary to power them, and our software infrastructure," Karp said in a letter to shareholders, "one that allows organizations to tether the power of artificial intelligence to objects and relationships in the real world." "For a startup, even one only a thousandth of our size, this growth rate would be striking, the talk of the town," Karp said. "For a business of our scale, however, it is, we continue to believe, nearly without precedent or comparison." "This was a phenomenal quarter ... We are guiding to the highest sequential quarterly revenue growth in our company's history," Karp said. In another boon to the company's US government business, Palantir announced last week that it signed a deal rolling up contracts with the US Army for a value of up to $10 billion over the next decade. Wedbush analyst Dan Ives, a noted Palantir bull, said the deal is 'one of the largest ever DOD [Department of Defense] software contracts in US history.' 'We believe this deal represents an additional tailwind for PLTR with AI initiatives across the US government accelerating with AI a strategic focus on the federal front and Palantir in the sweet spot to benefit from a tidal wave of federal spending on AI,' Ives wrote in a note to investors Friday. Palantir stock is up more than 110% this year against the S&P 500's 7.4% gain. Some on Wall Street have concerns about Palantir's valuation, and shares currently trade at levels 24 times the historical market multiple of the S&P 500 (^GSPC). 'We cannot rationalize why Palantir is the most expensive name in our software coverage,' RBC Capital Markets analyst Rishi Jaluria wrote in a note to clients before Palantir published its Q2 earnings. 'Absent a substantial beat-and-raise quarter elevating the NT [near term] growth trajectory, valuation seems unsustainable.' Jake Conley is a breaking news reporter covering US equities for Yahoo Finance. Follow him on X at @byjakeconley or email him at